Q3 FY2026 · ended Sep 30, 2026 · Revenue $1.34B, +11.2% YoY · Filed Oct 29, 2026
Dexcom, Inc. (DXCM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $1.3 billion and net income of $275.1 million. Free cash flow was $272.7 million. As of Sep 30, 2026 it held $1.2 billion in cash and investments and $149.2 million in total debt.
Revenue
$1.34B
+11.2% vs year-ago quarter
Net income
$275.10M
-3.1% vs year-ago quarter
Operating cash flow
$325.60M
-50.7% vs year-ago quarter
Free cash flow
$272.70M
-52.9% vs year-ago quarter
EPS
$0.72
+2.9% vs year-ago quarter
Dividend per share
None
Shares outstanding
372.95M
-4.4% vs year-ago quarter
Net cash
$1.03B
Q3 FY2026
Operating margin
24.0%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- DXCM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1093557
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Fresenius SE & Co. KGaA FSNUY
- West Pharmaceutical Services Inc WST
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $1.2B | $1.3B | $1.2B |
| Operating income | $327.2M | $318.3M | $255.3M | $323.0M | $242.5M |
| Net income | $275.1M | $249.1M | $199.5M | $267.3M | $283.8M |
| Diluted EPS | $0.72 | $0.64 | $0.51 | $0.67 | $0.70 |
| Operating cash flow | $325.6M | $269.2M | $525.6M | $294.0M | $659.9M |
| Free cash flow | $272.7M | $184.5M | $449.0M | $192.1M | $579.4M |
| Total assets | $6.2B | $6.5B | $6.6B | $6.3B | $7.5B |
| Total liabilities | $3.7B | $3.8B | $3.7B | $3.6B | $4.8B |
| Stockholders' equity | $2.5B | $2.6B | $3.0B | $2.7B | $2.7B |
| Cash and investments | $1.2B | $1.3B | $1.3B | $1.1B | $2.1B |
| Total debt | $149.2M | $155.6M | $143.0M | $155.5M | $128.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Oct 29, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 14, 2026 | Sep 10, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 10, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
All 1000 Dexcom, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.